InvestmentJun 5, 2026, 04:02 PM
Jade Biosciences Closes Public Offering, Raises $172.5M Gross
AI Summary
Jade Biosciences, a clinical-stage biotechnology company, announced the closing of its previously announced public offering. The company sold 11,500,000 shares of common stock, including shares from the underwriters' full option exercise, at $15.00 per share. This offering generated gross proceeds of $172.5 million for Jade. The company plans to use the net proceeds, along with existing cash, to fund clinical trials, preclinical studies, manufacturing, research and development, capital expenditures, and general corporate purposes.
Key Highlights
- Jade Biosciences closed its public offering of 11,500,000 shares of common stock.
- The shares were sold at a price of $15.00 per share.
- The offering generated gross proceeds of $172.5 million for Jade Biosciences.
- Underwriters fully exercised their option to purchase 1,500,000 additional shares.
- Net proceeds will fund clinical trials, preclinical studies, and manufacturing.
- Funds will also be used for additional R&D, capital expenditures, and general corporate purposes.
Price Impact
More from JBIO